Lorus Therapeutics Inc - Report of Foreign Issuer (6-K)
03 Octobre 2008 - 6:21PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Report of Foreign
Issuer
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of
1934
For the
Month of October, 2008
Commission File Number 1-32001
(Translation
of registrant’s name into English)
2 Meridian Road, Toronto, Ontario M9W
4Z7
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Note
: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely
to provide an attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Note:
Regulation S-T Rule
101(b)(7) only permits the submission in paper of a Form 6-K if submitted to
furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the
registrant is incorporated, domiciled or legally organized (the registrant’s
“home country”), or under the rules of the home country exchange on which the
registrant’s securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already
been the subject of a Form 6-K submission or other Commission filing on
EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨
No
x
If
“Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):82-_______________.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
Lorus
Therapeutics Inc.
|
|
|
|
|
Date: October
3, 2008
|
By:
|
/s/
“Elizabeth Williams”
|
|
|
Elizabeth
Williams
|
|
|
Director
of Finance and Controller
|
EXHIBIT INDEX
99.1
|
Lorus
Therapeutics Inc. - Voting
Results
|
Lorus Therapeutics (AMEX:LRP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Lorus Therapeutics (AMEX:LRP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024